Navigation Links
MAQUET Cardiovascular Receives FDA 510(k) Clearance For New Mega® Intra-Aortic Balloon Catheter Sizes
Date:5/14/2012

MAHWAH, N.J., May 14, 2012 /PRNewswire/ -- MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new MEGA 7.5Fr. 30cc and 40cc intra-aortic balloon (IAB) catheters. These new, larger volume catheters will allow clinicians to provide patients with greater hemodynamic support, regardless of their height. 

"The MEGA family of catheters represents a true advancement in IAB therapy and broadens our therapeutic offerings for clinicians and patients, as these new catheters deliver a significant increase in hemodynamic support regardless of the patient's height," said Christian Keller, President and CEO of MAQUET Cardiovascular. "As a global leader in hemodynamic support, MAQUET is committed to advancing IAB therapy, and we are confident that our larger volume balloons will remain the gold standard for clinicians when such support is needed."

The advanced design of the MEGA IAB family provides exceptional benefits for patients and clinicians. Larger volume balloons like MEGA displace more blood in the aorta during diastole, resulting in improved augmentation and unloading. Due to the unique balloon wrap, MEGA IABs have no step-down between the balloon membrane and the catheter shaft, which potentially decreases bleeding when using a sheathless approach. The new MEGA IABs also provide a patented, more durable Durathane balloon membrane and a co-lumen catheter design with a large 0.027 inch inner lumen for a reliable pressure transducer signal.

Additionally, all MEGA IABs come with two STATLOCK® IAB Stabilization Devices[1], which allow the catheter to be secured to the patient's leg without sutures. STATLOCK® provides safety and comfort for the patient and eliminates the risk of suture needle sticks for the clinician.

"We are constantly striving to provide our customers with new solutions that will improve clinical practice and patient outcomes," said Raoul Quintero, President and CEO of MAQUET Medical Systems USA, the distributer of MAQUET's IAB therapy products. "These new MEGA balloons round out our product offering and provide clinicians the ability to enhance hemodynamic support and patient care in a efficacious, safe and cost effective manner, regardless of patient size."

IAB counterpulsation is an adjunctive therapy that is often used in patients with left ventricular failure and other cardiac conditions. When the IAB is inserted into the patient's aorta and counterpulsates with the heart, it augments coronary blood flow to increase myocardial oxygen supply and decrease myocardial oxygen demand.

The new IAB catheters will be available in May 2012. For more information about the MEGA IAB family, please visit http://ca.maquet.com.

About MAQUET 

As a trusted partner for hospitals and clinicians since 1838, Maquet is a global leader in medical systems that advance surgical interventions, cardiovascular procedures and critical care. Maquet develops and designs innovative products and therapeutic applications for the operating room, hybrid OR/Cath lab, intensive care unit and patient transport within acute care hospitals, improving outcomes and quality of life for patients.

Cardiovascular specialties include intra-aortic balloon counterpulsation therapy for cardiac assist; coronary artery bypass surgery; aortic and peripheral vascular surgery; and extracorporeal circulation.

The Critical Care portfolio includes market-leading intensive care ventilators and anesthesia machines.

Maquet also equips Surgical Workplaces with critical infrastructure such as flexible room design for OR and ICU; OR tables; lights and ceiling supply units; and OR integration for image data management.

Maquet is a subsidiary of the publicly listed Swedish Getinge Group. In 2011, Maquet generated nearly 1.4 billion Euro which is more than half of the Group's annual revenue of 2.4 billion Euros. The Getinge Group has 13,000 employees worldwide, including around 6,000 Maquet employees in 50 international sales and service organizations, as well as a network of more than 280 sales representatives. For more information please visit www.maquet.com and www.getingegroup.com.

MAQUET – The Gold Standard
www.maquet.com
www.getinge.com

[1] STATLOCK is a registered trademark of C.R. Bard Inc.


'/>"/>
SOURCE MAQUET Cardiovascular
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MAQUET Cardiovascular Announces FDA 510(k) Clearance and CE Mark for the CARDIOSAVE™ Intra-Aortic Balloon Pump
2. MAQUET Cardiovascular Completes Acquisition of Atrium Medical Corporation
3. MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps
4. MAQUET Cardiovascular Receives FDA 510(k) Clearance and CE Mark for Its New SENSATION PLUS™ Intra-Aortic Balloon Catheter
5. UPDATE - MAQUET Cardiovascular Receives 510(k) Clearance to Market the CARDIOHELP System in U.S.
6. MAQUET Cardiovascular Receives 510(k) Clearance to Market the CARDIOHELP System in U.S.
7. MAQUET Cardiovascular Launches New VASOVIEW 6 PRO Endoscopic Vessel Harvesting System
8. MAQUET Cardiovascular Launches Advanced VASOVIEW Technology for Endoscopic Vessel Harvesting Procedures in Cardiac Surgery
9. MAQUET Cardiovascular Introduces New VASOSHIELD Pressure Controlling Syringe to Help Preserve Graft Integrity for Coronary Artery Bypass Surgery Patients
10. MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices
11. MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... May 3, 2016 ... dass sie einen entscheidenden Meilenstein durch diese ... Aufruf zum Handeln, um Patientenresultate  bei Verdauungs- ... zu Fortschritten im Verständnis der Hepatischen Enzephalopathie ... Bewusstsein für Hepatische Enzephalopathie in der Öffentlichkeit ...
(Date:5/2/2016)... Mass. , May 2, 2016  While nearly ... that osteoporosis can have on their health, only about ...   according to the results of a new survey ... To mark the start of National Osteoporosis Month, Hologic ... health, which affects nearly 56 million Americans. ...
(Date:4/29/2016)... 29, 2016 ReportsnReports.com adds ... market research report that provides an overview of ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... Horizon Blue Cross Blue ... as one of the nation’s most accomplished business technology innovators by InformationWeek, earning ... recognition for technology achievements that have enabled the delivery of the company’s innovative ...
(Date:5/3/2016)... ... , ... Elizabeth Murray has always loved walking one to two miles a ... shoulder and one on her arm. But she got to the point where she ... prolapse. , The valves of the heart wouldn’t close properly resulting in mitral regurgitation, ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... online university, has announced today the launch of its Associates and Bachelor's degrees ... President Emeritus of The Rockefeller University, Dr. Torsten N. Wiesel; Chairman and CEO ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Boston Children’s ... can rehearse tough medical situations or practice tricky or rare procedures in an environment ... Area, the SIM Center is also available to inventors and “hackers” to develop and ...
(Date:5/3/2016)... ... 2016 , ... Park Cities Pet Sitter has openings for both full-time and ... 75206, 75209, 75219, 75220, 75225, 75229, 75230, 75231 and 75235 zip codes. These ... Preston Hollow and Park Cities areas of the Metroplex. Candidates must love animals, ...
Breaking Medicine News(10 mins):